Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697230 | 1.00 | SCN9A (0.70) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2938345 | 1.00 | SCN9A (0.70) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2933340 | 0.96 | SCN9A (0.65) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2933335 | 0.96 | SCN9A (0.65) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2934211 | 0.96 | SCN9A (0.65) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL19562955 | 0.95 | SCN9A (0.66) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL4189153 | 0.90 | SCN9A (0.74) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL964787 | 0.90 | SCN9A (0.74) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2995936 | 0.90 | SCN9A (0.74) | SCN9AMAOBMAOASCN3ACD274 | |
| SCHEMBL2995932 | 0.90 | SCN9A (0.74) | SCN9AMAOBMAOASCN3ACD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | claimed |
| CN-104523668-B | High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof | 纽朗制药有限公司 | 2020-06-09 | — | — | CN | claimed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | claimed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | claimed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | claimed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | claimed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | claimed |
| US-20140051758-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-02-20 | — | — | US | claimed |
| CN-103284984-A | Process for the production of 2-[4-(3- and 2-flu0r0benzyl0xy)benzylamin0]propanamides | NEWRON PHARM SPA | 2013-09-11 | — | — | CN | claimed |
| US-8530701-B2 | High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2013-09-10 | — | — | US | claimed |
| US-8278485-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-02 | — | — | US | claimed |
| EP-2474521-A1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | Newron Pharmaceuticals S.p.A. (IT) | 2012-07-11 | — | — | EP | claimed |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-06-21 | — | — | US | claimed |
| US-8076515-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-12-13 | — | — | US | claimed |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-23 | — | — | US | claimed |
| EP-2229351-A1 | PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-22 | — | — | EP | claimed |
| WO-2009074478-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | WO | claimed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | claimed |
| EP-2029524-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | claimed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | SCN9A 407/4885MAOB 129/4885MAOA 200/4885 |
| US-20140051758-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF | KCNH3, KCNB2, KCNH2 | SCN9A 146/4885MAOB 149/4885MAOA 473/4885 |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | PDE7A, PDE8B, PDE9A | SCN9A 147/4885MAOB 53/4885MAOA 179/4885 |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | SCN9A 407/4885MAOB 129/4885MAOA 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.